Compare AbCellera Biologics Inc (ABCL) vs Advanced Drainage Systems Inc (WMS) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Advanced Drainage Systems (WMS) trades at $149.07, down 2.04% over 24 hours. The stock shows strong profitability with a 13.98% net income margin and consistent earnings beats in recent quarters. Technical indicators are bullish overall, with moving averages supporting an uptrend. Recent news includes a dividend increase and mixed analyst sentiment, with a consensus price target of $183.00. Cash flow trends indicate robust operational performance despite a recent dip in net cash flow.

Outlook remains positive due to solid fundamentals and growth in stormwater management demand. Risks include competitive pressures and potential margin compression. The stock presents a moderate buy opportunity with upside to analyst targets, balanced by near-term volatility and sector-specific headwinds.